Biosimilar Red Tape Elimination Act
Sponsored By: Senator Sen. Lee, Mike [R-UT]
Introduced
Summary
Changes how biosimilars become ‘interchangeable’ by creating a new, two-part deemed‑interchangeability framework and reorganizing the approval rules in section 351(k) of the Public Health Service Act. The bill would set a 60‑day transition clock after enactment, preserve certain existing exclusivity periods, and force updates to FDA guidance on interchangeability and biosimilarity.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Faster biosimilar approval rules
If enacted, the HHS Secretary would have to update FDA guidance to reflect the bill within 18 months. The agency would revise or revoke prior interchangeability guidances and issue clear rules on what data applicants must submit. The Secretary would also be required to find that an application includes enough information to show biosimilarity. The bill would treat most 351(k) biosimilars as not a 'new active ingredient' for certain FDA rules, with narrow pediatric exceptions, and make related technical edits.
Faster biosimilar interchangeability rules
If enacted, many biosimilars licensed under the 351(k) pathway would be treated as interchangeable with the original drug. The transition date would be 60 days after enactment. Products licensed on or after that date would usually be interchangeable when licensed, unless they rely on the same reference product as another product that has a first interchangeable exclusivity period in effect; then they would wait until that exclusivity ends. Any unexpired first interchangeable exclusivity that was already running before enactment would continue for its remaining time.
Free Policy Watch
You just read the policy. Now see what it costs you.
Pick a topic. PRIA runs your household against live legislation and sends you a free personalized readout.
Pick a topic to get started
Sponsors & CoSponsors
Sponsor
Sen. Lee, Mike [R-UT]
UT • R
Cosponsors
Sen. Luján, Ben Ray [D-NM]
NM • D
Sponsored 6/4/2025
Sen. Paul, Rand [R-KY]
KY • R
Sponsored 6/4/2025
Sen. Hassan, Margaret Wood [D-NH]
NH • D
Sponsored 6/4/2025
Eric Schmitt
MO • R
Sponsored 6/24/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in